The recently dismissed frivolous lawsuit filed by Rosen had caused a lot of damage that made financing more expensive. The company has had to reprioritize what it moves forward on.
In Reply to '58nout' Thanks Karin. Yep there it is. What makes Sullivan able to use it:
The decision by management was made after factoring in today’s regulatory and litigious climate
with which Cellceutix has unfortunately become quite familiar.
News 
Market Data 
Discover 
